SCHEMBL16201341

SCHEMBL16201341

CCCN(C)Cc1c[nH]nc1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MOK Q9UQ07 1/20 0.37
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
CSNK1D P48730 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
CARM1 Q86X55 3/20 0.35
PRMT1 Q99873 3/20 0.35
ALOX15 P16050 1/20 0.34
CHRM2 P08172 1/20 0.34
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
PRMT6 Q96LA8 2/20 0.33
PRMT8 Q9NR22 2/20 0.33
TTK P33981 1/20 0.33
PRMT3 O60678 1/20 0.33
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201436 0.90 ALDH1A1 (0.42) MOKALDH1A1KMT2A
SCHEMBL16772890 0.87 MAPK11 (0.38) MOKCSNK1DMAPK11MAPK14
SCHEMBL16201421 0.87 MEN1 (0.36) MOKALDH1A1CARM1PRMT1PRMT6
SCHEMBL16201147 0.87 CARM1 (0.49) ADORA2AADORA1CARM1PRMT1CD274
SCHEMBL16201347 0.86 CRHR1 (0.38) ADORA1ALDH1A1CARM1PRMT1DRD2
SCHEMBL16201317 0.86 KDM4E (0.34) MOKMAPK11MAPK14ALDH1A1DRD2
SCHEMBL16201382 0.85 SMN1; SMN2 (0.41) MAPK14ALDH1A1CARM1PRMT1PRMT6
SCHEMBL16772840 0.85 CHRNB2 (0.39) ALDH1A1KMT2A
SCHEMBL16201353 0.85 ALDH1A1 (0.35) ALDH1A1SIGMAR1HTR2AACHEKMT2A
SCHEMBL16201414 0.85 PRMT1 (0.41) ALDH1A1CARM1PRMT1PRMT6PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 MOK 1964/4885ADORA2A 3442/4885ADORA1 3259/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 MOK 2043/4885ADORA2A 3374/4885ADORA1 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.